US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine
11 nov. 2020 06h00 HE
|
Immuron Limited
Key Points NMRC demonstrated functional antibodies in new oral therapeutic targeting Campylobacter and ETECImmuron executes a Research Agreement with PCI Clinical Services to manufacture drug...
Immuron Travelers’ Diarrhea Market Update
12 oct. 2020 06h00 HE
|
Immuron Limited
Key Points Immuron’s IMM-124E IND Program recommencesUniformed Services University to recommence planned Travelers’ Diarrhea clinical studyCOVID-19 - Consultancy Agreement with Infectious Disease...
US DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new oral therapeutic
20 juil. 2020 06h00 HE
|
Immuron Limited
Key Points NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted in 2021One trial will...
Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense
19 juin 2020 06h00 HE
|
Immuron Limited
Key Points Immuron executes a Research Agreement with The Henry M. Jackson Foundation for Advancement of Military Medicine Inc.Immuron executes a Research Agreement with CSIRO to develop a new oral...
US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to Prevent Acute Infectious Diarrhea
09 juin 2020 06h00 HE
|
Immuron Limited
Key Points NMRC requests Pre-IND meeting with FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted in 2021One trial...
US Department of Defense Reports Final Results from Travelan® Shigellosis Challenge Study
12 juin 2019 07h00 HE
|
Immuron Limited
Key Highlights: Travelan® shigellosis challenge studies in non-human primates successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of Travelan® treated animals...
US Department of Defense Reports Travelan Protects Against Shigella in Primates
05 sept. 2018 10h00 HE
|
Immuron Limited
Key Highlights: Travelan® pre-clinical shigellosis challenge studies in non-human primates (NHP) successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of...
US Department of Defense Research Collaboration Moves Forward
24 juil. 2018 06h28 HE
|
Immuron Limited
Key Highlights: Three US Defense Health funded research projects on Travelan® successfully completedStudies commissioned by the US Department of Defense to evaluate Travelan®’s ability to...
Immuron’s Travelan® Sales Continue to Soar in Third Quarter of FY2018 in Australian & US Markets
23 avr. 2018 09h30 HE
|
Immuron Limited
Key Highlights: US Travelan® sales continue an upward trend with a 95% increase in the Third Quarter of 2018 compared to the same period last year. YTD US sales (End March 2018) climbed to...
US Defense Reports Broad Travelan® Reactivity to 180 Pathogenic Bacteria Including Camylobacter and Shigella
29 janv. 2018 09h20 HE
|
Immuron Limited
Key Highlights: The research program was performed by the U.S. Department of Defense (DoD) and was conducted by the Department of Enteric Diseases, Armed Forces Research Institute of Medical Sciences...